Convergent Technologies announces the establishment of its new division, Convergent Molecular.

In early 2020, Convergent Technologies introduced its Convergys® POC RT-PCR Nucleic Acid Detection System, a fully-integrated system from the viral RNA extraction to onsite reference and central lab-grade results in real-time. Convergys® POC RT-PCR integrates WHO endorsed RT-PCR methodology into a convenient and easy-to-use format. The pre-filled, single-use cartridges take care of the complete patient sample processing, including RNA extraction, purification and RT-PCR amplification- all within 90 minutes. Convergent has been a trusted partner in fast and reliable patient triage, isolation and therapy management solutions during the COVID -19 pandemic. These systems are currently in active use at CDCs, University Research Institutes, Clinics, Tourism Organizations, National Defence, Critical Support Infrastructures and NGOs in EU and in many other geographies worldwide.

The test menu has been expanded in Q2 of 2021 to include test panels for combined COVID-19, Influenza and RSV detection, test panels for pathogenic Mycobacteria, test panels for vector borne infections and tests for sexually transmitted diseases (STDs).

A comprehensive range of tests in the field of Veterinary Diagnostics has also been introduced in the Q3 2021 for pet and farm animal healthcare.

Convergent Technologies plays a leading role in the field of Integrated Healthcare Solutions. We strive to provide innovative and cost-effective healthcare solutions enabling people live healthier lives. Our state-of-the-art diagnostic tests and systems concentrate on early detection, targeted screening, evaluation and monitoring of diseases. Convergys® lab equipment has gained worldwide acceptance with the laboratories. Our Quality Management System complies with the requirements of EN 13485:2016 and guidelines stipulated by CE 93/42/EWG and EU 2017/745 for Medical Products, CE 98/79/EG and EU 2017/746 for in vitro Diagnostics.

Convergent Molecular as a separate division within Convergent Technologies shall add more focus and impetus in the development of molecular diagnostic solutions targeting various application areas.